Liposomal amphotericin B as first line and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV.
Visceral leishmaniasis has emerged in both endemic and non-endemic areas as an opportunistic infection in HIV-positive subjects. At risk for infection are HIV-positive intravenous drug abusers with a low CD4 T cell count and a high HIV viral load. In these patients, who are not always symptomatic, leishmaniasis is probably due to endogenous reactivation and often presents in an atypical fashion. Death results from uncontrolled bleeding or bacterial infections. The clinical and biological spectrum of this disease suggests that it should be included among the diagnostic criteria for AIDS. Visceral leishmaniasis responds poorly to therapy and, when responsive, the relapse rate is high. Treatment protocols and criteria to document cure after treatment have not been definitely established. Lastly, there is no effective immuno- or chemo-prophylaxis against this protozoan. We report the case of an HIV-infected patient affected by visceral leishmaniasis who was successfully treated with liposomal amphotericin B given both as first line and as secondary prophylactic therapy. The patient has remained disease-free for 26 months after his first remission whereas, to our knowledge, almost all immunocompromised patients relapse within 12 months.
Dipartimento di Medicina Interna, Università degli Studi di Genova.
P
P
Borrelli
A
A
Imperato
G
G
Murdaca
M
M
Scudeletti
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control*; D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage*; D000981:Antiprotozoal Agents / Q000008:administration & dosage*; D004337:Drug Carriers; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000517:prevention & control*; D008081:Liposomes; D008297:Male
D000981:Antiprotozoal Agents; D004337:Drug Carriers; D008081:Liposomes; D000666:Amphotericin B